Get the Stockscreener App
33.97
0.61%
0.193
Tg Therapeutics Inc stock is traded at $33.97, with a volume of 622.02K.
It is up +0.61% in the last 24 hours and up +1.21% over the past month.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.
See More
Previous Close:
$33.78
Open:
$33.7
24h Volume:
622.02K
Relative Volume:
0.34
Market Cap:
$5.42B
Revenue:
$616.29M
Net Income/Loss:
$447.18M
P/E Ratio:
12.23
EPS:
2.7771
Net Cash Flow:
$-24.99M
1W Performance:
-7.20%
1M Performance:
+1.21%
6M Performance:
-2.29%
1Y Performance:
-25.09%
1-Day Range:
$33.23
$34.00
1-Week Range:
$33.23
$36.99
52-Week Range:
$25.28
$45.97
Tg Therapeutics Inc Stock (TGTX) Company Profile
Name
Tg Therapeutics Inc
Sector
Industry
Phone
(212) 554-4484
Address
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
33.97 | 5.52B | 616.29M | 447.18M | -24.99M | 2.7771 |
VRTX
Vertex Pharmaceuticals Inc
|
424.92 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
705.45 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
785.61 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.08 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
294.16 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-25 | Resumed | H.C. Wainwright | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Oct-29-24 | Initiated | TD Cowen | Buy |
| Aug-02-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-26-23 | Resumed | Jefferies | Buy |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-19-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-01-20 | Initiated | JP Morgan | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Initiated | Evercore ISI | Outperform |
| Jan-17-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Feb-06-19 | Resumed | Jefferies | Buy |
| Sep-25-18 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-01-17 | Resumed | B. Riley FBR, Inc. | Buy |
| Nov-14-17 | Resumed | H.C. Wainwright | Buy |
| Apr-25-17 | Initiated | Jefferies | Buy |
| Mar-06-17 | Reiterated | FBR & Co. | Outperform |
| Oct-06-16 | Resumed | Brean Capital | Buy |
| May-27-16 | Initiated | SunTrust | Buy |
| Dec-01-15 | Initiated | FBR Capital | Outperform |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| Aug-12-15 | Resumed | H.C. Wainwright | Buy |
| Jun-19-15 | Reiterated | Brean Capital | Buy |
| Dec-11-14 | Reiterated | ROTH Capital | Buy |
| Dec-10-14 | Reiterated | ROTH Capital | Buy |
View All
Tg Therapeutics Inc Stock (TGTX) Latest News
Executive pay, auditor and board up for votes at TG Therapeutics (TGTX) 2026 meeting - Stock Titan
TG Therapeutics schedules Q1 results call, 2026 outlook for May 6 - Stock Titan
Pictet Asset Management Holding SA Trims Stock Position in TG Therapeutics, Inc. $TGTX - MarketBeat
Vanguard Portfolio Management discloses 5.26% stake in TG Therapeutics (NASDAQ: TGTX) - Stock Titan
TG Therapeutics Inc (TGTX) News, Articles, Events & Latest Updates - Stocktwits
TG Therapeutics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth - Yahoo Finance
TG Therapeutics secures $750M credit facility with Blue Owl, boosts buyback to $300M - MSN
TG Therapeutics, Inc. (TGTX) Stock Analysis: Unveiling a 21.71% Upside Potential in the Biotech Space - DirectorsTalk Interviews
TGTX completes enrollment in Phase III study on subcutaneous Briumvi - MSN
TG Therapeutics (TGTX) Is Up 7.6% After Advancing Subcutaneous BRIUMVI Phase 3 Trial Enrollment Completion - Sahm
TGTX Forecast, Price Target & Analyst Ratings | TG THERAPEUTICS INC (NASDAQ:TGTX) - ChartMill
(TGTX) Volatility Zones as Tactical Triggers - Stock Traders Daily
TG Therapeutics Inc. (TGTX) posts 87.3 percent year over year revenue growth despite large Q4 2025 earnings miss. - Xã Thanh Hà
Q1 EPS Estimates for TG Therapeutics Cut by HC Wainwright - MarketBeat
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting - ChartMill
TGTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance - MSN
HC Wainwright Forecasts Lower Earnings for TG Therapeutics - MarketBeat
TG Therapeutics Inc (NASDAQ:TGTX) Shows Strong Growth and Technical Setup for Potential Upside - ChartMill
TGTX Stock Price, Quote & Chart | TG THERAPEUTICS INC (NASDAQ:TGTX) - ChartMill
TG Therapeutics Stock: Flawless Execution $500M Non-Dilutive Boost Outlook (NASDAQ:TGTX) - Seeking Alpha
A Look At TG Therapeutics (TGTX) Valuation After Recent Share Price Momentum - Yahoo Finance
Has The Market Mispriced TG Therapeutics (TGTX) After Recent Biotech Sector Coverage Swings? - Sahm
Goldman Sachs Maintains TG Therapeutics(TGTX.US) With Hold Rating, Raises Target Price to $40 - Moomoo
TGTX Completes Enrollment in Phase III Study on Subcutaneous Briumvi - The Globe and Mail
TG Therapeutics concludes enrolment in Phase III Briumvi trial - Yahoo Finance
TG Therapeutics Completes Enrollment for Phase 3 Multiple Sclerosis Trial - Moomoo
TG Therapeutics (TGTX) Stock Competitive Analysis (Marginal Gain) 2026-04-15Gap Down Stocks - Xã Thanh Hà
TG Therapeutics completes enrollment in subcutaneous BRIUMVI trial By Investing.com - Investing.com Australia
TGTX Advances with Phase 3 Trial Completion for Briumvi Treatment - GuruFocus
TG Therapeutics completes enrollment in subcutaneous BRIUMVI trial - Investing.com
MS trial completion moves TG closer to at-home BRIUMVI option - Stock Titan
Update Report: Should you avoid TG Therapeutics Inc stock right now2026 Fed Impact & Weekly Return Optimization Plans - baoquankhu1.vn
Price-Driven Insight from (TGTX) for Rule-Based Strategy - Stock Traders Daily
TG Therapeutics (TGTX) reports financial results for Q4 and full year 2025 - MSN
Fed Watch: Does TG Therapeutics Inc stock benefit from AI growth2026 Trade Ideas & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Gains Recap: Is TG Therapeutics Inc a turnaround storyQuarterly Market Summary & Safe Capital Investment Plans - baoquankhu1.vn
TG Therapeutics, Inc. (TGTX) Stock Forecasts - Yahoo! Finance Canada
BofA Securities Maintains TG Therapeutics(TGTX.US) With Sell Rating, Maintains Target Price $15 - Moomoo
Fed Meeting: Can TG Therapeutics Inc expand into new marketsMarket Trend Report & Daily Momentum Trading Reports - baoquankhu1.vn
Gains Recap: Is TG Therapeutics Inc undervalued by DCF analysis - baoquankhu1.vn
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
TGTX PE Ratio & Valuation, Is TGTX Overvalued - Intellectia AI
TG Therapeutics Inc (NASDAQ:TGTX): An Affordable Growth Stock with Strong Momentum - ChartMill
TG Therapeutics, Inc. (TGTX) Stock forecasts - Yahoo Finance UK
TG THERAPEUTICS INC (1TGTX.MI) Balance Sheet - Yahoo! Finance Canada
TG Therapeutics, Inc. (TGTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
TG Therapeutics Inc. (TGTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
(TGTX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
TG Therapeutics: Briumvi Performance Aiding Upside, Buybacks Limiting Downside (TGTX) - Seeking Alpha
Tg Therapeutics Inc Stock (TGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):